Digital Health Keeps Measuring Engagement While Ignoring Tolerability
Engagement still matters. But the more important question is whether the intervention respects the human…
Digital Health Keeps Measuring Engagement While Ignoring Tolerability
Engagement still matters. But the more important question is whether the intervention respects the human nervous system of the person on the receiving end. The post Digital Health Keeps Measuring Engagement While Ignoring Tolerability appeared first on MedCity News.
AI Health Check: No Governance, No Trust
Will doctors or patients who are burned by one AI solution trust the next one they’re given? Probably not. That’s why every provider rolling out AI tools has to understand this risk and build governance into its development process. The post AI Health Check: No Governance, No Trust appeared first on MedCity News.
The Silent Threat — Why Early Lymphedema Detection Matters for Breast Cancer Survivors
As breast cancer treatment continues to improve, our focus must expand beyond survival to encompass the quality of life during and after treatment. The post The Silent Threat — Why Early Lymphedema Detection Matters for Breast Cancer Survivors appeared first on MedCity News.
Cheaper, Alternative Health Plans Are Having a Moment, but Critics Urge Caution
When Melanie Miller saw that her health insurance premium payment was set to nearly triple to $914 a month this year, she stopped shopping on the Affordable Care Act marketplace. The 59-year-old retired teacher, who recently moved from Ohio to Michigan, now pays $341 a month for a pair of plans, one that covers routine…
AI at Scale: Does It Deliver?
How is AI applied to clinical care and hospital operations across a real health system at full scale? Chip Kahn talks to Dr. Michael Schlosser, Senior Vice President and Chief Transformation Officer at HCA Healthcare, about how AI is developed for everyday use, starting with careful testing and customization, with clinicians and nurses engaged from…
AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer
Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad collaboration between Daiichi Sankyo and AstraZeneca. The post AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer appeared first on…
Precision Medicine’s Next Hurdle Isn’t Science — It’s Execution
A new UPMC report found that while most health systems now offer precision medicine programs, many still face challenges scaling them due to reimbursement, data integration and patient engagement issues. Health system leaders say the field’s future depends on embedding genomics into routine care, as well as proving its clinical and financial value. The post…
Maximizing Value vs. Minimizing Cost in Healthcare Purchasing
Is a private-label product really better once you factor in performance, durability, and everything it takes to support it? Sometimes yes and sometimes no. The job is knowing the difference. The post Maximizing Value vs. Minimizing Cost in Healthcare Purchasing appeared first on MedCity News.
What the Failure of Wearables Can Teach Us About AI
The takeaway from the current failure of wearables is that signal without synthesis doesn’t change outcomes. If healthcare treats AI as just another way to collect or repackage data, it will repeat the same mistake. The post What the Failure of Wearables Can Teach Us About AI appeared first on MedCity News.
Clinical Operations Burnout Is Undermining Patient Enrollment
When coordinators are buried in documentation, scheduling, and data reconciliation, patient engagement is the first thing to go. And when engagement drops, retention drops with it. The post Clinical Operations Burnout Is Undermining Patient Enrollment appeared first on MedCity News.
